Fox Run Management L.L.C. Has $346,000 Holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Fox Run Management L.L.C. lessened its stake in shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) by 46.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,837 shares of the company’s stock after selling 3,278 shares during the quarter. Fox Run Management L.L.C.’s holdings in iRhythm Technologies were worth $346,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Van ECK Associates Corp grew its holdings in iRhythm Technologies by 41.3% during the fourth quarter. Van ECK Associates Corp now owns 554 shares of the company’s stock valued at $50,000 after purchasing an additional 162 shares during the last quarter. Bank Pictet & Cie Europe AG grew its stake in iRhythm Technologies by 5.9% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 3,289 shares of the company’s stock valued at $297,000 after buying an additional 184 shares during the last quarter. KBC Group NV raised its holdings in iRhythm Technologies by 45.1% in the 4th quarter. KBC Group NV now owns 1,319 shares of the company’s stock worth $119,000 after acquiring an additional 410 shares during the period. Values First Advisors Inc. lifted its position in iRhythm Technologies by 9.1% during the 4th quarter. Values First Advisors Inc. now owns 5,588 shares of the company’s stock worth $504,000 after acquiring an additional 467 shares during the last quarter. Finally, R Squared Ltd bought a new stake in iRhythm Technologies during the fourth quarter valued at about $45,000.

Analyst Ratings Changes

A number of research firms have recently commented on IRTC. Canaccord Genuity Group lifted their price objective on iRhythm Technologies from $125.00 to $152.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. StockNews.com raised iRhythm Technologies from a “sell” rating to a “hold” rating in a research report on Monday, February 24th. Oppenheimer increased their price objective on iRhythm Technologies from $105.00 to $120.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Needham & Company LLC boosted their target price on shares of iRhythm Technologies from $125.00 to $138.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, The Goldman Sachs Group increased their price target on shares of iRhythm Technologies from $91.00 to $124.00 and gave the company a “neutral” rating in a report on Monday, February 24th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $119.73.

iRhythm Technologies Price Performance

NASDAQ:IRTC opened at $104.96 on Thursday. The company has a debt-to-equity ratio of 9.00, a quick ratio of 6.12 and a current ratio of 6.27. The company has a 50-day moving average of $108.18 and a 200-day moving average of $89.58. iRhythm Technologies, Inc. has a 52 week low of $55.92 and a 52 week high of $128.52. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of -28.84 and a beta of 1.36.

iRhythm Technologies (NASDAQ:IRTC) last announced its quarterly earnings results on Thursday, February 20th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.30. iRhythm Technologies had a negative net margin of 19.14% and a negative return on equity of 118.83%. The firm had revenue of $164.33 million during the quarter, compared to analysts’ expectations of $158.30 million. As a group, equities research analysts anticipate that iRhythm Technologies, Inc. will post -1.98 earnings per share for the current fiscal year.

iRhythm Technologies Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.